Shares of Biogen (BIIB +0.4%) have recovered after diving abruptly around 1:30 on reports a patient has died while on the company's MS drug Tecfidera although no link has been established between the incident and the drug. Wells Fargo's Brian Abrahams — no stranger to commenting on Tecfidera — does not "expect a dramatic impact on [the treatment's] uptake trajectory," and speculates that there were "other infectious issues contributing" to the patient's death.